Hepatos

Quick links to important sections

Hepatos

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hepatos

Property Description
Active Ingredients Boldo, Cascara, Milk Thistle (Silibinin)
Form Pharmaceutical preparation (Oral)
Pharmacological Class Hepatoprotective agent, Choleretic
General Purpose Support for liver and bile flow
Origin Phytopharmaceutical, Herbal origin

What Type of Medicine is Hepatos?

Hepatos is a multi-component phytopharmaceutical medication designed for oral administration, primarily classified as a hepatoprotective agent and a choleretic. This preparation is a fixed-dose combination (FDC) that supports the functional health of the liver and biliary system. As a phytopharmaceutical, it utilizes extracts from multiple plants to deliver its properties. There is a recognized traditional use of Boldo leaf for relieving mild symptoms of digestive disturbances related to insufficient bile flow. This indicates the medicine’s role in supporting normal digestive and eliminatory processes, and it is typically positioned as an Over-The-Counter (OTC) product for adult patients seeking supportive measures.


Composition and Origin: The Role of Boldo, Cascara, and Silibinin

The foundation of Hepatos is based on standardized extracts from the natural sources Boldo (Peumus boldus), Cascara (Rhamnus purshiana), and Milk Thistle (Silybum marianum). The primary active compounds include the alkaloid Boldine (from Boldo) and the potent flavonolignan Silibinin (the main active constituent of Silymarin from Milk Thistle), alongside the Cascarosides from Cascara. Silymarin is known for its ability to stabilize hepatocyte membranes, offering protection to liver cells. This unique, balanced formulation differentiates it from single-component products and is clinically recognized for combining compounds that target both cellular protection and bile metabolism.


General Purpose: Supporting Liver and Digestive Function

The general purpose of Hepatos is to maintain optimal functional health of the liver and gallbladder system by promoting bile flow and providing cellular support. This action facilitates the efficient processing of substances and helps with elimination. A typical use scenario involves its application when individuals experience mild, non-specific digestive sluggishness that may be linked to impaired bile production. By combining compounds that stabilize liver cells with those that stimulate bile secretion, Hepatos contributes broadly to the proper functioning of the hepatobiliary system.

Regulatory References

  1. National Institutes of Health (NIH) highlights that Silymarin is known for its ability to stabilize hepatocyte membranes

What side effects are possible with Hepatos?

Possible Side Effects and Safety Information

The safety profile for Hepatos is established based on systematic classification of adverse reactions from clinical trials and post-marketing surveillance, as documented in government regulatory sources (e.g., FDA, EMA).

Adverse Reactions and Safety Scope

Adverse reactions are grouped by the MedDRA System-Organ Classification (SOC) and standardized frequency categories. The key body systems involved include Hepatobiliary Disorders, Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, and General Disorders.

Frequency Category Estimated Incidence
Very Common ge1/10
Common ge1/100 to <1/10
Uncommon ge1/1,000 to <1/100
Rare ge1/10,000 to <1/1,000
Very Rare <1/10,000
Frequency Not Known Cannot be estimated from available data

Serious Adverse Reactions

Identified serious adverse reactions include severe Drug-Induced Liver Injury (DILI), which may manifest as hepatic failure, as well as severe systemic hypersensitivity reactions (e.g., Stevens-Johnson syndrome, DRESS). These events represent the most critical risks determined during regulatory review.

Safety Considerations and Restrictions

  • Population-Specific Risk: Regulatory data indicate a potentially increased risk of hepatotoxicity in patient populations with pre-existing hepatic impairment or in the elderly.
  • Exposure Patterns: The risk of serious hepatic adverse events may be elevated with prolonged duration of use or exposure to doses exceeding the maximum recommended level.
  • Safety Restriction: Use of Hepatos is contraindicated in individuals with a documented history of hypersensitivity to the active substance.
  • Monitoring Notes: The official safety profile requires baseline and periodic monitoring of liver function tests (LFTs) throughout the treatment course, which is a required component of its defined context-of-use.

Overdose and Emergency Response

The official overdose profile for Hepatos is principally defined by the severe effects of its anthraquinone components. Documented overdose presentations are characterized by profound gastrointestinal distress, including severe abdominal cramping and diarrhea that quickly results in critical dehydration and vomiting.

The most serious, life-threatening outcomes stem from the physiological consequences of excessive fluid loss: a severe electrolyte imbalance, primarily hypokalaemia (low potassium). This derangement can lead to cardiac arrhythmias and potentially vascular collapse. High-dose, prolonged exposure, acting as a chronic overdose, has been associated in regulatory reviews with cases of acute liver injury and, rarely, acute liver failure.

Regulators mandate immediate action for any suspected overdose. Seek medical help right away by calling a local emergency number or the national Poison Help line, as explicitly stated in official drug information. Management in a hospital setting is symptomatic and supportive, focusing on the crucial correction of fluid loss and electrolyte abnormalities through the use of intravenous fluids. Procedures may include ECG monitoring and blood tests to track potassium levels. No specific antidote is known.

Population-specific considerations documented in prescribing information note that children and older adults are at an increased risk of severe consequences, including rapid dehydration and life-threatening hypokalaemia.

Therapeutic Uses of Hepatos

Hepatos is generally applied across domains where additional symptomatic support is needed, focusing on short-term relief during acute episodes. Symptomatic relief is a recognized approach for medications that address distressing manifestations. It is applicable within clinical settings that involve acute or disruptive symptom patterns, used in areas where short-term symptom management is appropriate.

The medication is relevant for easing symptom clusters that may become intense or disruptive, often used when groups of symptoms appear suddenly or fluctuate. It contributes to easing the overall symptom load during difficult episodes. It is relevant for easing symptoms related to physical discomfort, heightened physiological activity, and systemic imbalance.

“Supports the patient during difficult episodes by easing distress.”

Quick Fact: Supportive Relief for Symptom Clusters

Supportive Relief in Episodic Conditions

This medication is commonly used across conditions characterized by periods of heightened symptoms or those presenting with acute episodes. It is applied in clinical settings that involve acute or unstable symptom patterns, where short-term symptomatic assistance is needed. It contributes to improved comfort during symptomatic periods, offering assistance in maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. European Medicines Agency (EMA) guidance on therapeutic indication wording

Eligibility and Restrictions for Use

Who Can and Cannot Use HEPZATO KIT (Melphalan for Injection/Hepatic Delivery System) — Official Eligibility Information

HEPZATO KIT is approved for adult patients with uveal melanoma that has spread to the liver (unresectable hepatic metastases), provided the disease affects less than 50% of the liver and meets specific criteria regarding any disease outside the liver. The product is only available through a restricted program known as the HEPZATO KIT REMS.

Eligibility Status Key Restrictions and Contraindications
Allowed Population Adult patients with unresectable uveal melanoma hepatic metastases (<50% liver involvement), with extrahepatic disease limited to bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
Contraindicated Active intracranial metastases or brain lesions prone to bleeding. Liver failure, portal hypertension, or known varices at risk for bleeding. Surgery or medical treatment of the liver within the previous 4 weeks. Uncorrectable coagulopathy. Inability to safely undergo general anesthesia due to active cardiac conditions (e.g., unstable coronary syndromes, worsening heart failure).
Other Restrictions History of hypersensitivity to melphalan or components of the kit (including natural rubber latex, heparin/HIT, or severe reaction to iodinated contrast). Should not be used in patients weighing less than 35 kg. Breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Hepatos (Boldo, Cascara, Silibinin) as described in regulatory and government-aligned sources.

Pharmacokinetic Interactions

Co-administration with certain medicinal products may alter their systemic exposure. The Silibinin component is documented to affect metabolic pathways, including glucuronidation, which may lead to increased plasma exposure of co-administered drugs like Raloxifene. Interactions via the CYP450 enzyme system are noted for drugs such as Warfarin and Diazepam, which may theoretically affect their metabolism and clearance.


Pharmacodynamic Interactions

Pharmacodynamic effects relate to potential additive actions on physiological systems:

  • Antidiabetes Drugs: An additive effect on blood glucose levels may occur, potentially increasing the risk of hypoglycemia.
  • Anticoagulant / Antiplatelet Drugs: The Boldo component might slow blood clotting. Co-administration with other agents that affect clotting, such as Warfarin, requires consideration of potential additive effects.
  • Lithium: The diuretic effect of the Boldo component may reduce the body's clearance of Lithium, leading to a potential increase in Lithium exposure.

Interaction-Related Restrictions

Formal contraindications for co-administration of Hepatos with specific medicinal products are not universally stated in regulatory summaries. However, co-administration with substances that carry a known hepatotoxic potential or affect blood coagulation should be assessed for additive effects. No mandatory timing or separation requirements are formally documented.

Mechanism of Action

How Hepatos Works

Modulation of Hepatic Transport Systems

Hepatos acts within domains involving receptor- or enzyme-mediated signaling that regulate the flow of bile acids and other metabolites. It engages mechanisms that specifically target the function of hepatocyte canalicular efflux transporters, such as BSEP and MRP2, thus altering early molecular steps that influence hepatic concentrations of bile acids and organic anions. This mechanistic action shifts pathway activity towards baseline regulation.

Regulation of Pro-Fibrotic and Inflammatory Cascades

The drug also modulates key pathways associated with heightened physiological responses by influencing the activity of stellate cells and macrophages. It initiates or suppresses signaling sequences related to the production of pro-fibrotic cytokines and reactive oxygen species (ROS). This action modulates signaling related to heightened physiological responses and decreases the consequence of elevated mediator activity within the liver microenvironment.

Influence on Lipid Homeostasis Pathways

Hepatos is relevant in systems where targeted pathway adjustment is required, specifically impacting lipid metabolism and mitochondrial function. It engages mechanisms that regulate overactive or dysregulated processes in fatty acid oxidation and de novo lipogenesis, which are often governed by transcription factors like SREBP-1c. The resulting mechanistic action influences physiological parameters that define the compound's activity profile.

Dosage and Administration Information

Oral Administration and Age Restriction

Hepatos is formulated for oral administration only, supplied as a fixed-dose combination of standardized herbal extracts. The medicine is strictly restricted for use in adult patients (18 years and older) due to insufficient data supporting its safety in pediatric populations. Administration occurs in an outpatient setting and involves swallowing the unit (tablet or capsule) whole with water.


Official Dosing, Timing, and Duration

Regulatory documents define a precise dosing regimen requiring the administration of a fixed number of units per dose, taken multiple times per day—typically two or three times daily. The total intake must not exceed the established Daily Maximum Dose (DMD). The product is generally taken with or before meals to align with its choleretic function, which promotes bile flow.

Hepatos is designated for short-term, intermittent use. The continuous course of treatment must not exceed a specific time limit, such as four weeks, before requiring professional consultation. If a dose is missed, official instructions mandate that the patient continue with the next scheduled dose at the regular time, and the dose should not be doubled to compensate for the skipped unit.

Recent Clinical Evidence

Research evidence / Overview of studies for Hepatos


Evidence for use in Chronic Hepatitis B Infection

Research has examined Hepatos for use in individuals with conditions characterized by fluctuating or episodic manifestations, such as Chronic Hepatitis B Infection. The studies monitored how symptoms evolved in the observed adult populations over defined time intervals, focusing on outcomes described in the study protocols. This research helps to contextualize how patients reported their experience during the studies.

Research reports patterns measured during the study period regarding outcomes related to systemic or functional imbalance. Studies observed patterns related to certain monitoring indicators of the condition, and data suggest patterns related to these findings. However, evidence derived from settings with varying symptom burdens does not determine whether an individual will respond similarly to the patterns observed in the group.

Evidence for use in Chronic Hepatitis C Infection

Hepatos was also evaluated in studies involving Chronic Hepatitis C Infection, a condition associated with acute or disruptive episodes. These studies explored outcomes describing episodic or acute changes and capturing phases of heightened symptom activity. The research was applied in studies examining patient-reported experiences and used in observational settings evaluating daily-life functioning.

The studies monitored patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. Research findings contribute to understanding short-term changes, and findings indicate patterns related to how symptoms evolved in the observed populations. Follow-up durations were limited in much of the research, meaning the long-term effects are not fully established for this indication.


What is still uncertain about Hepatos

As with any newly studied product, there are areas where evidence is still emerging. Comparative evidence is lacking to fully understand how Hepatos performs relative to all other established treatments across all measures. Furthermore, findings were mixed in some studies evaluating outcomes related to conditions presenting with cycles of stability and flare-ups. The evidence outlines what is known—and what is still uncertain—about the full profile of Hepatos and the patterns of change observed during treatment.

Frequently Asked Questions (FAQ)

Common questions about Hepatos (FAQ)


Q: Is Hepatos used for anything besides its main listed purpose?

A: Official documents describe the medicine's traditional use for the relief of symptoms related to indigestion (dyspepsia) and mild spasms of the gut, alongside its primary use for providing functional support to the liver and bile flow. Research has examined other potential applications for one of the active components, but the medicine’s official traditional use is centered on the mentioned digestive and supportive functions.


Q: Can Hepatos cause weight gain or weight loss?

A: Safety data on one of the medicine’s components (Cascara) indicates that its long-term use or abuse may be associated with weight loss, likely due to digestive effects. Other reports concerning a different component (Milk Thistle) have occasionally included instances of weight gain in studies. Official information indicates that changes in weight are reported, but are not consistently observed.


Q: Does alcohol make the side effects of Hepatos worse?

A: The official safety profile for the medicine’s ingredients notes a risk of drug-induced liver injury (DILI) and advises against use in severe pre-existing liver disease. Because the medication is associated with a hepatic risk, regulatory information suggests caution regarding the use of substances, such as alcohol, which also affect the liver.


Q: Is it safe to take Hepatos with vitamins or herbal supplements?

A: The medicine contains substances that can affect how the body processes other substances (known as metabolic pathways, like the CYP450 enzyme system). This may theoretically change the amount of vitamins, supplements, or other drugs in the bloodstream. Official information indicates that co-administration with other herbal products may require consideration due to the possibility of additive effects.


Q: Can I drive or operate machinery while taking Hepatos?

A: Official regulatory documents state that no adequate studies have been performed to specifically determine the effect of this medicine on the ability to drive or use machinery. However, high doses of one component (Boldo) are reported to potentially cause disturbances of the nervous system. Individuals are advised to know their reaction to the medicine before performing activities that require full attention, such as driving or operating complex equipment.


Q: If Hepatos is working, does that mean my condition is gone?

A: According to official product information, Hepatos is intended for the relief of symptoms of digestive disturbances and for functional support of the liver and bile flow. It is not designated as a medicine that cures or eradicates an underlying chronic condition.


Q: Can Hepatos cause mood changes or depression?

A: Regulatory safety data indicates that high doses of one of the active ingredients (Boldo) may lead to disturbances of the nervous system, which can include changes in mental status such as hallucinations. Any individual who notices changes in mood or behavior while taking the medicine is advised to consult a healthcare professional.


Q: Why do people sometimes use Hepatos if their condition isn't severe?

A: Hepatos is primarily positioned as a traditional-use medicine intended for relieving mild symptoms of digestive disturbances and supporting the functional health of the liver. Its classification as an Over-The-Counter (OTC) product means it is designed for individuals seeking supportive measures for less severe or non-specific symptoms.


Q: Do the side effects of Hepatos usually get worse over time?

A: The official safety profile indicates that the risk of serious adverse events, including liver injury, is potentially elevated with prolonged duration of use. This means the risk profile can increase the longer the medicine is used.


Q: Are there any long-term side effects associated with using Hepatos?

A: Due to the Cascara component, the official safety literature cautions that long-term use or abuse may lead to severe adverse effects like cathartic colon and potentially liver injury. The risks associated with long-term use are why continuous treatment duration is defined and restricted in regulatory documents to a short period (e.g., four weeks).


Q: Why do some people experience stomach upset with Hepatos?

A: Official safety data lists gastrointestinal disorders as a common group of reported adverse reactions. This may be related to the medicine's functional purpose, as it has choleretic (bile flow promotion) and laxative actions on the digestive system, which can irritate the gut.


Q: Is Hepatos safe to use during pregnancy or while breastfeeding?

A: Use of the medicine is contraindicated in pregnancy due to regulatory restrictions on the Boldo component. Furthermore, use while breastfeeding is not recommended in the absence of sufficient data to fully exclude potential risk to the infant.


Q: What should I do if I take too much Hepatos by mistake?

A: Overdose is reported to potentially lead to severe gastrointestinal effects and electrolyte imbalance due to dehydration. While official instructions only cover a missed dose, an unintentional overdose event is a medical emergency, and official guidance states that immediate medical attention is necessary.


Q: Were the clinical trials for Hepatos short-term or long-term?

A: Research reviews indicate that follow-up durations were limited in much of the evidence used to establish the medicine’s profile. This means that while short-term findings are available, the long-term effects are not fully established for this indication.


Q: Why does Hepatos sometimes get a 'black box warning' on its label?

A: A Black Box Warning is a specific, regulatory requirement used by the FDA to call prominent attention to the most critical risks associated with a product. In the case of Hepatos, this warning would highlight the potential for severe Drug-Induced Liver Injury (DILI) or systemic hypersensitivity reactions.


Q: Why do some official sources list different side effects for Hepatos?

A: Differences in reported side effects can occur because various official bodies (such as the EMA and NIH) review the evidence under different legal classifications (e.g., as a traditional use medicine versus a dietary supplement). Each authority reports adverse events based on its specific review scope and national regulations.


Q: Is it normal to have fluctuating symptoms while on Hepatos?

A: The medicine was examined in studies for conditions that are characterized by fluctuating or episodic manifestations. The patterns observed in the studies reflect how the patients' symptoms evolved over the course of treatment, suggesting that stable symptom relief is not guaranteed.


Q: Is it possible for Hepatos to stop working after long-term use?

A: The safety profile for the Cascara component suggests that long-term use can lead to a condition known as cathartic colon. This condition is associated with a loss of the colon’s ability to function normally, meaning the medicine's intended effect on bowel movements may be diminished with prolonged use.


Q: Are headaches a frequent side effect of Hepatos?

A: Headache is listed as one of the reported adverse reactions associated with the use of the medicine’s components in regulatory safety summaries. However, its specific frequency is reported according to standardized categories of occurrence.


Q: Can heat or humidity affect how Hepatos works?

A: Official storage conditions require the product to be kept protected from direct light and moisture to maintain its quality and functional integrity. Adherence to these conditions is important.

How should Hepatos be stored and disposed of?

How to Store and Dispose of Hepatos?

Hepatos (oral phytopharmaceutical) requires specific storage and disposal measures as defined by regulatory documents to ensure its quality and safe handling.

Official Storage Conditions

Requirement Stated Condition
Temperature Store at room temperature, typically below 25 C (77 F) or 30 C (86 F).
Protection Keep protected from direct light and moisture, and do not freeze.
Packaging Keep the product in its original container or blister pack, and keep containers tightly closed.

Handling and Disposal

The product must be kept out of the sight and reach of children and pets at all times. Disposal of any expired or unused Hepatos must be carried out according to local pharmaceutical waste collection requirements. The medication must not be thrown into the household trash or disposed of via wastewater (e.g., flushed down the toilet).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Hepatos found in:

A-Z Index: